This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Riken Corporation, Other. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2017
Title: Hanayuki Okura: Innovator in Myocardial Cell Preparation
Introduction
Hanayuki Okura is a prominent inventor based in Hyogo, Japan. He has made significant contributions to the field of cell preparation, particularly in the context of myocardial cells. His innovative work focuses on methods that enhance the production of cells that can effectively differentiate into myocardial cells, which are crucial for heart function.
Latest Patents
Hanayuki Okura holds a patent for a "Cell preparation containing myocardium-committed cell." This invention relates to a method for producing a cell population comprising myocardium-committed cells that can differentiate into and survive as myocardial cells in a myocardial tissue environment. The method involves culturing adipose-tissue-derived multi-lineage/multi-potent progenitor cells in the presence of a polyamine. This patent not only outlines the production of these specialized cells but also describes a method for treating heart disease by administering the cell population to a subject.
Career Highlights
Throughout his career, Hanayuki Okura has worked with notable organizations, including Riken Corporation. His work at Riken has allowed him to collaborate with leading researchers and contribute to advancements in regenerative medicine and cell therapy.
Collaborations
One of his notable collaborators is Akifumi Matsuyama. Their partnership has likely fostered innovative approaches in their respective research areas, particularly in the development of cell-based therapies.
Conclusion
Hanayuki Okura's contributions to the field of myocardial cell preparation highlight his role as an innovator in regenerative medicine. His patented methods and collaborations reflect a commitment to advancing treatments for heart diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile